1 It is a debilitating chronic condition, with studies suggesting a lower average quality of life than that seen in people with heart failure, renal failure, multiple sclerosis, stroke, and many forms of cancer
You can read the abstract of this article at LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM)
This suggests that our premature intestinal epithelial model is functional and capable of detecting maturation signals that induce BEST4+ cells
Although the enzymes of the pathway are found at multiple locations within the cell, there is as yet little convincing evidence that they operate in the apoplastic space (Foyer and Kunert 2024)
Suitability: Injections suit diagnosed deficiency